FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th.
Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. He also served as a tenured professor and Vice Chairman for Research in the number one Genetics Department in the US, Department of Molecular and Human Genetics at Baylor College of Medicine, Houston, Texas.* At Baylor, he led an extensive clinical and translational research team, delivering top-quality clinical genomics and multi-omics tools. Working in collaboration with many professional societies, he has been a pioneer in creating best practices guidelines in Clinical Next-Generation Sequencing for somatic cancer, constitutional genomics, bioinformatics, and whole-genome sequencing.
"I am thrilled and honored to join the NeoGenomics team and be a part of the organization focused on providing the best of the class, complete suite of diagnostic tests from pathology to cytogenetics to NGS for the entire cancer care continuum." - Dr. Kulkarni
Dr. Kulkarni is considered a world-renowned expert and key opinion leader in cancer genomics with a focus on the application of genomic and multi-omic technologies to improve the understanding of human disease and the precision of clinical diagnosis, prognosis, and treatment. He brings the unique combination of world-class clinical, scientific, commercial, and regulatory talents to the role. Dr. Kulkarni has served as an expert panelist on several preeminent regulatory agencies such as FDA, CDC, CMS, and NIH. He has given numerous national and international presentations and, as a leading voice, presented his insight, thoughts, and opinions as a frequent guest on multiple major news outlets across the country. Additionally, he has published extensively in peer-reviewed articles and numerous well-known journals. He is the Editor-in-Chief of Cancer Genetics Journal and has co-edited a book, available on Amazon, titled Clinical Genomics - A Guide to Clinical Next-Generation Sequencing.
"NeoGenomics is thrilled to have such a well-respected, global oncology genomics authority like Dr. Kulkarni leading its research and innovation teams. Dr. Kulkarni will be a vital member of the executive team, drawing on years of research expertise, clinical genomics experience, a strong network, business acumen, and a passion for innovation in precision medicine" said Mark Mallon Chief Executive Officer of NeoGenomics.
"I am thrilled and honored to join the NeoGenomics team and be a part of the organization focused on providing the best of the class, complete suite of diagnostic tests from pathology to cytogenetics to NGS for the entire cancer care continuum, Dr. Shashi Kulkarni said. "I am extremely excited to use cutting-edge, multi-omic precision oncology tools to impact the over half a million patients with cancer that NeoGenomics serves annually."
Dr. Kulkarni did his Clinical Fellowship at Harvard Medical School. He completed his translational genomics training at Imperial College in London, UK, and at All India Institute of Medical Sciences, the premier medical school in New Delhi, India. He is an American Board of Medical Genetics and Genomics board-certified medical geneticist with dual certifications in Clinical Molecular Genetics & Genomics and Clinical Cytogenetics & Genomics. He is also a fellow of the American College of Medical Genetics and genomics and has an executive MBA.
* For nine years running, the Department remains the No. 1 ranked U.S. genetics department, as measured by the number of NIH-awarded grants and total funding received. For 2019, the amount in funding dollars from NIH awards totaled more than $78 million (source Blueridge rankings).
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life-altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP-accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward Looking Statements
Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "plan," "potential" and other words of similar meaning. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on February 25, 2021, as such information has been updated in subsequent SEC filings. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. NeoGenomics routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.neogenomics.com. The Company encourages investors and potential investors to consult the NeoGenomics website regularly for important information about NeoGenomics.
For further information, please contact:
NeoGenomics, Inc.
Doug Brown
Chief Strategy and Corporate Development Officer
T: 239.768.0600 x2539
M: 704.236.2064
[email protected]
Charlie Eidson
Director, Investor Relations and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
[email protected]
SOURCE: NeoGenomics, Inc.